Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07MVK
|
||||
| Former ID |
DAP000953
|
||||
| Drug Name |
Halofantrine
|
||||
| Synonyms |
Halfan; Halofantrino; HALOFANTRINE HYDROCHLORIDE; Halofantrine HCl; Halofantrine Hydrochloride [USAN]; Halofantrine [USAN]; Halofantrino [Spanish]; WR 171669; Dl-WR 171669; Halfan (TN); Halofantrine hydrochloride (USAN); WR 171,699; WR-171669; WR-171699; SK&F-102866; WR-171,669; (+-)-Halofantrine hydrochloride; (1)-Halofantrine; 1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenanthrene-methanol; 1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenathrenemethanol; 1,3-Dichloro-6-trifluoromethyl-9-(3-(dibutylamino)-1-hydroxypropyl)phenanthrene HCl; 1,3-Dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-9-phenanthrenemethanol hydrochloride; 1,3-Dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)phenanthren-1-methanol hydrochloride; 1-(1,3-Dichloro-6-trifluoromethyl-9-phenanthryl)-3-(di-n-butylamino)propanol hydrochloride; 1-(1,3-dichloro-6-trifluoromethyl-9-phenanthryl)-3-di(n-butyl)aminopropanol HCl; 3-(Dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol hydrochloride; 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol; 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol hydrochloride; 9-(3-(dibutylamino)-1-hydroxypropyl)-1,3-dichloro-6-(trifluoromethyl)phenanthrene hydrochloride; 9-Phenanthrenemethanol, 1,3-dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-(1); 9-Phenanthrenemethanol, 1,3-dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-, hydrochloride; 9-Phenanthrenemethanol, 1,3-dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-,hydrochloride
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Malaria [ICD10:B54] | Approved | [1] | ||
| Therapeutic Class |
Antimalarials
|
||||
| Company |
GlaxoSmithKline
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C26H30Cl2F3NO
|
||||
| Canonical SMILES |
CCCCN(CCCC)CCC(C1=C2C=CC(=CC2=C3C=C(C=C(C3=C1)Cl)Cl)C(F<br />)(F)F)O
|
||||
| InChI |
1S/C26H30Cl2F3NO/c1-3-5-10-32(11-6-4-2)12-9-25(33)23-16-22-21(14-18(27)15-24(22)28)20-13-17(26(29,30)31)7-8-19(20)23/h7-8,13-16,25,33H,3-6,9-12H2,1-2H3
|
||||
| InChIKey |
FOHHNHSLJDZUGQ-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 69756-53-2
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9836, 603092, 4441467, 7979519, 8174993, 11406986, 11467059, 11468179, 11486828, 14859927, 34678697, 46506753, 47572921, 47572922, 47869196, 48317942, 48416078, 49699380, 50070734, 50123958, 77799953, 87245098, 92719358, 96024726, 103305814, 103994306, 104326444, 117505175, 125356362, 126424569, 126620878, 126653035, 126670922, 127875900, 134338227, 135029301, 135329562, 137251553, 152047097, 160643701, 160964551, 162178795, 163414203, 164786759, 172883008, 174006943, 179117060, 184545611, 196110120, 223400586
|
||||
| SuperDrug ATC ID |
P01BX01
|
||||
| SuperDrug CAS ID |
cas=069756532
|
||||
| Target and Pathway | |||||
| Target(s) | Calmodulin | Target Info | Modulator | [2] | |
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Calcium signaling pathway | |||||
| cGMP-PKG signaling pathway | |||||
| cAMP signaling pathway | |||||
| Phosphatidylinositol signaling system | |||||
| Oocyte meiosis | |||||
| Adrenergic signaling in cardiomyocytes | |||||
| Vascular smooth muscle contraction | |||||
| Circadian entrainment | |||||
| Long-term potentiation | |||||
| Neurotrophin signaling pathway | |||||
| Dopaminergic synapse | |||||
| Olfactory transduction | |||||
| Phototransduction | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| Insulin signaling pathway | |||||
| GnRH signaling pathway | |||||
| Estrogen signaling pathway | |||||
| Melanogenesis | |||||
| Oxytocin signaling pathway | |||||
| Glucagon signaling pathway | |||||
| Salivary secretion | |||||
| Gastric acid secretion | |||||
| Alzheimer's disease | |||||
| Amphetamine addiction | |||||
| Alcoholism | |||||
| Pertussis | |||||
| Tuberculosis | |||||
| Glioma | |||||
| NetPath Pathway | RANKL Signaling Pathway | ||||
| TSH Signaling Pathway | |||||
| PANTHER Pathway | CCKR signaling map ST | ||||
| Pathway Interaction Database | BCR signaling pathway | ||||
| p38 MAPK signaling pathway | |||||
| Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||||
| Role of Calcineurin-dependent NFAT signaling in lymphocytes | |||||
| IL2 signaling events mediated by PI3K | |||||
| IFN-gamma pathway | |||||
| Lissencephaly gene (LIS1) in neuronal migration and development | |||||
| ErbB1 downstream signaling | |||||
| VEGFR1 specific signals | |||||
| Regulation of cytoplasmic and nuclear SMAD2/3 signaling | |||||
| Calcium signaling in the CD4+ TCR pathway | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Insulin-mediated glucose transport | |||||
| N-cadherin signaling events | |||||
| Cellular roles of Anthrax toxin | |||||
| Regulation of Ras family activation | |||||
| Downstream signaling in naï | |||||
| PathWhiz Pathway | Muscle/Heart Contraction | ||||
| Reactome | Calmodulin induced events | ||||
| Platelet degranulation | |||||
| Translocation of GLUT4 to the plasma membrane | |||||
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | |||||
| DARPP-32 events | |||||
| eNOS activation | |||||
| Inactivation, recovery and regulation of the phototransduction cascade | |||||
| FCERI mediated Ca+2 mobilization | |||||
| Ca2+ pathway | |||||
| CREB phosphorylation through the activation of CaMKII | |||||
| Ras activation uopn Ca2+ infux through NMDA receptor | |||||
| Smooth Muscle Contraction | |||||
| VEGFR2 mediated vascular permeability | |||||
| VEGFR2 mediated cell proliferation | |||||
| RHO GTPases activate IQGAPs | |||||
| RAF/MAP kinase cascade | |||||
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | |||||
| WikiPathways | Translocation of GLUT4 to the Plasma Membrane | ||||
| Visual phototransduction | |||||
| Fc epsilon receptor (FCERI) signaling | |||||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
| Signaling by the B Cell Receptor (BCR) | |||||
| Inositol phosphate metabolism | |||||
| DAG and IP3 signaling | |||||
| Opioid Signalling | |||||
| Muscle contraction | |||||
| Metabolism of nitric oxide | |||||
| Metabolism of carbohydrates | |||||
| References | |||||
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020250. | ||||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.